172 related articles for article (PubMed ID: 29753836)
1. A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients.
Hill JA; Pergam SA; Cox E; Xie H; Leisenring WM; Boeckh M; Delaney C; Milano F
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2094-2100. PubMed ID: 29753836
[TBL] [Abstract][Full Text] [Related]
2. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients.
Milano F; Pergam SA; Xie H; Leisenring WM; Gutman JA; Riffkin I; Chow V; Boeckh MJ; Delaney C
Blood; 2011 Nov; 118(20):5689-96. PubMed ID: 21937692
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy.
Rinehart M; Hochard E; Rockey M; Abhyankar S; Ganguly S; Lin T; McGuirk J; Shune L; Singh A; Aljitawi O
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):105-11. PubMed ID: 27013276
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
5. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
8. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
Reed DR; Petroni GR; West M; Jones C; Alfaraj A; Williams PG; DeGregory K; Grose K; Monson S; Varadarajan I; Volodin L; Donowitz GR; Kindwall-Keller TL; Ballen KK
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):61-69. PubMed ID: 36634280
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
13. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
Seu P; Winston DJ; Holt CD; Kaldas F; Busuttil RW
Transplantation; 1997 Dec; 64(11):1614-7. PubMed ID: 9415569
[TBL] [Abstract][Full Text] [Related]
14. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
Martin M; Mañez R; Linden P; Estores D; Torre-Cisneros J; Kusne S; Ondick L; Ptachcinski R; Irish W; Kisor D
Transplantation; 1994 Oct; 58(7):779-85. PubMed ID: 7940710
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
19. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
Hammerstrom AE; Lombardi LR; Pingali SR; Rondon G; Chen J; Milton DR; Chemaly RF; Champlin RE; Gulbis A; Ciurea SO
Biol Blood Marrow Transplant; 2018 Feb; 24(2):353-358. PubMed ID: 28986189
[TBL] [Abstract][Full Text] [Related]
20. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
